# OnCo record paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024" ;
  schema:name "TRIANGLE: ibrutinib with immunochemotherapy with or without autologous transplant versus immunochemotherapy and transplant in untreated mantle cell lymphoma"@en ;
  schema:description "Adding ibrutinib to first-line treatment for younger people with mantle cell lymphoma kept more of them free of treatment failure at three years, and the stem cell transplant that was standard was not shown to add benefit once ibrutinib was used."@en ;
  schema:url <https://onco.cc/key-papers/paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(24)00184-3>, <https://pubmed.ncbi.nlm.nih.gov/38705160/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(24)00184-3> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Dreyling M, Doorduijn J, Giné E, et al." ;
  onco:cancers <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/> ;
  onco:trials <https://onco.cc/trials/triangle/> ;
  onco:journals <https://onco.cc/journals/lancet/> .